Related Experiment Videos

[Cancer of the ovary. New therapeutic approaches]

E Pujade-Lauraine

Presse Medicale (Paris, France : 1983)

|January 22, 1994

Abstract

No abstract available in PubMed .

Related Concept Videos

Articles linked to this work by shared authors, journal, and citation graph.

Maintenance of PARP Inhibitor Rechallenge plus Bevacizumab in Patients with Platinum-Sensitive, Recurrent Ovarian Cancer Previously Treated with a PARP Inhibitor.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

Predictive value of BRCA1/RAD51C methylation in HGSOC - An ancillary study of the PAOLA-1/ENGOT-ov25 phase 3 trial.

European journal of cancer (Oxford, England : 1990)·2025

Dostarlimab and niraparib in primary advanced ovarian cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2025

HR-SC-an academic-developed machine learning framework to classify HRD-positive ovarian cancer patients and predict sensitivity to olaparib.

ESMO open·2025

Efficacy of subsequent therapies in patients with advanced ovarian cancer who relapse after first-line olaparib maintenance: results of the PAOLA-1/ENGOT-ov25 trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2024

Maintenance olaparib rechallenge in patients with platinum-sensitive relapsed ovarian cancer previously treated with a PARP inhibitor (OReO/ENGOT-ov38): a phase IIIb trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2023

See all related articles